Stock Analysis
Quest Diagnostics Incorporated (DGX) Stock Analysis
Quest Diagnostics Incorporated (DGX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Quest Diagnostics Incorporated (DGX) currently has an AIQ Score of 50/100, indicating a neutral setup. Risk is the strongest factor at 60/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
DGX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $235.02 |
| AIQ Score | 50/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $26.07B |
| P/E Ratio | 23.3 |
| Forward P/E | — |
| EPS | $2.88 |
| Revenue TTM | $3.04B |
| Dividend Yield | 0.00% |
| Beta | 0.55 |
| Volume | 997.03K |
| 52-week range | $171.18-$247.19 |
| RSI 14 | 33.59 |
| 50-Day SMA | $229.27 |
| 200-Day SMA | $202.02 |
| Analyst Price Target | $237.56 |
| Next Earnings | Oct 20, 2026 |
DGX
OverviewDGX Stock Analysis Summary
Quest Diagnostics Incorporated (DGX) currently has an AIQ Score of 50/100, indicating a neutral setup. Risk resilience is the strongest factor at 60/100. Momentum is the weakest current factor at 42/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, DGX has AIQ Score of 50/100 with Risk resilience base of 60/100 and fading Momentum at 42/100. Wait for component alignment before adding exposure.
Healthcare · 1.68% stock move · DGX classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is DGX Bullish or Bearish Right Now?
DGX currently has a neutral overall setup. Risk Resilience is the strongest factor at 60/100, while Momentum is weakest at 42/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Risk Resilience is supportive at 60/100.
- - Price is +2.51% above its 50-day SMA.
- - Analyst target implies +1.08% upside from the latest quote.
- - Momentum is weak at 42/100.
- - Technical consensus has more sell votes than buy votes (24 vs 12).
Current Consensus
DGX's Technical Analysis Consensus is currently Sell, with 12 buy, 9 neutral, and 24 sell votes. DGX's 14-day RSI is 33.59, which places the stock in a weaker momentum range. DGX's beta is 0.55, indicating lower market sensitivity than the broad market.
What Changed in DGX?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the DGX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
DGX Decision Framework
Public evidence layers, setup checks, and risk context for Quest Diagnostics Incorporated.
Quest Diagnostics Incorporated (DGX) Stock Analysis
Quest Diagnostics Incorporated has an AIQ Score of 50/100 in a Neutral regime. Risk is strongest at 60/100. Beta is 0.55, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | DGX is in a Neutral AIQ regime with score 50/100. |
| Signal Conflict | The primary conflict is that risk leads at 60/100 while momentum lags at 42/100. |
| Factor Evidence | Momentum 42/100 · Value 53/100 · Quality 47/100 · Risk 60/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 60/100.
Momentum is 42/100 and RSI (14) is 33.6.
DGX is in a Neutral regime at 50/100.
Risk factor is 60/100 with beta 0.55 and annual volatility 23.85%.
Current conflict: risk leads at 60/100 while momentum lags at 42/100.
DGX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
DGX Fundamentals
DGX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
DGX Technical Analysis
DGX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
DGX Stock Catalysts
Track DGX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
DGX Dividend Analysis
DGX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
DGX Financial Data
DGX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
DGX Risk Analysis
DGX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
DGX Stock News
DGX stock news, market tone, recent headlines, and catalyst context.
DGX vs Healthcare Services / Managed Care Peers
Current peer cohort: DGX · DOCS · DVA · EHC · ELV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| DGX Current stock | 50/100 | 53/100 | 42/100 | 60/100 | 1.07 | 23.85% | Current |
| DOCS Doximity | 59/100 | 46/100 | 55/100 | 56/100 | -1.31 | 63.74% | DGX vs DOCS |
| DVA DaVita | 59/100 | 68/100 | 66/100 | 57/100 | 0.83 | 45.08% | DGX vs DVA |
| EHC Encompass Health | 63/100 | 57/100 | 65/100 | 60/100 | -0.08 | 28.80% | DGX vs EHC |
| ELV Elevance Health | 63/100 | 68/100 | 76/100 | 63/100 | 0.95 | 35.26% | DGX vs ELV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching DGX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for DGX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
DGX Stock FAQ
What is DGX stock price today?
Quest Diagnostics Incorporated's current stock price is $235.02. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is DGX bullish or bearish right now?
DGX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is DGX's market cap?
DGX's market cap is $26.07B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is DGX's current P/E ratio?
DGX's current P/E ratio is 23.3 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is DGX's RSI?
DGX's 14-day RSI is 33.59 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is DGX above its 50-day and 200-day moving averages?
DGX is 2.51% from its 50-day SMA and 16.34% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is DGX's next earnings date?
DGX's next earnings date is currently listed as Oct 20, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does DGX pay a dividend?
DGX's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.